Tue Feb 25, 2020 03:29
English | 繁體 | 简体
ASCLETIS-B (1672)
Year: 2020|2019 |2018 |2017 |2016 |2015 |2014
18 Feb 2020
APPLICATION FOR CATEGORY I DRUG ASC41 FOR CLINICAL TRIALS OF NONALCOHOLIC STEATOHEPATITIS (NASH) INDICATION ACCEPTED
17 Feb 2020
INSIDE INFORMATION - RITONAVIR OBTAINED APPROVAL FROM RELEVANT REGULATORY AUTHORITIES OF ZHEJIANG PROVINCE TO CONDUCT STUDY ON THE TREATMENT OF NOVEL CORONAVIRUS PNEUMONIA
13 Feb 2020
ANNOUNCEMENT - INSIDE INFORMATION - ASC09/RITONAVIR COMBINED WITH INTERFERON ALPHA ATOMIZATION OBTAINED APPROVAL FROM THE SECOND AFFILIATED HOSPITAL ETHICS COMMITTEE OF CHONGQING MEDICAL UNIVERSITY TO CONDUCT CLINICAL TRIAL ON THE TREATMENT OF NOVEL CORONAVIRUS PNEUMONIA
07 Feb 2020
ANNOUNCEMENT - INSIDE INFORMATION - ASC09/RITONAVIR CLINICAL TRIAL FOR NEW CORONAVIRUS INFECTION INITIATED ACROSS ZHEJIANG PROVINCE AFTER WUHAN
05 Feb 2020
ANNOUNCEMENT - INSIDE INFORMATION - ASC09 FIXED-DOSE COMBINATION AND RITONAVIR OBTAINED APPROVAL FROM WUHAN TONGJI HOSPITAL ETHICS COMMITTEE TO CONDUCT CLINICAL TRIAL ON THE TREATMENT OF NEW CORONAVIRUS INFECTIONS
03 Feb 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020
03 Feb 2020
ANNOUNCEMENT - INSIDE INFORMATION - PROGRESS REGARDING ASC09 FIXED-DOSE COMBINATION AND RITONAVIR IN TERMS OF THE TREATMENT OF NEW CORONAVIRUS INFECTIONS
29 Jan 2020
CLARIFICATION ANNOUNCEMENT
23 Jan 2020
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIALS OF HBV IN CHINA FOR ASC22, A SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY
02 Jan 2020
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
Quote
HSI: 26,820.88 -487.93
3.88
0.12 (3.0%)
As of16:15 24 Feb 2020
Open: 4.00 52Wk High: 8.69
Day High: 4.00 52Wk Low: 2.80
Day Low: 3.85 P/E: 0.00
Prev. Close: 4.00 Yield: 0.00%
Volume: 5.63M
Mkt Cap: 4.43B
Turnover: 21.87M NAV: 3.482
Quotes are delayed by at least 15 minutes.
Contact ASCLETIS-B
Web: http://www.ascletis.com

To request additional information on this company, please complete the form below and we will contact the company on your behalf.

Name:*
Company:
Position:
Phone:
E-mail:*
Existing Shareholder: Yes No
Message:*  

* Required Fields
A founding member of:
China Tonghai IR:
Sitemap  |  About Us  |  Contact Us  |  Disclaimers     English | 繁體 | 简体  
Tonghai Financial:
China Tonghai International Financial Limited  |  China Tonghai Capital  |  China Tonghai Securities
Oceanwide Financial Management   |  Quamnet
 
Information of TonghaiIR (Investor Relations):
[Hong Kong Listed Company Information] [Financial News] [Announcement Alerts] [Free Delayed Stock Quote] [Chart]
[Hong Kong stock information]

TonghaiIR (Investor Relations) Services:
[Listed Companies Information] [Listed Companies Financial Information] [Listed Companies Announcements]
[Listed Companies Circulars] [Listed Companies News] [Press Releases] [Listed Companies Event Calendar]
[Listed Companies Presentations] [Proxy Forms]

China Tonghai IR (Investor Relations):
[Securities Firms] [Fund Houses] [Venture Capitals] [Financial Public Relations Agencies] [Financial Printers]
Investor Relations Dictionary:
[Listed Companies Result Announcement] [Financial Report] [Interim Report] [Annual General Meeting]
[Extraordinary General Meeting] [Board Meeting] [Annual Report] [Contact Listed Companies Investor Relations]
[Company Information Sheet] [Next Day Disclosure Return] [News Release] [IPO] [Prospectus] [Stock Quote] [Trading Volume]